SCHEMBL616275

SCHEMBL616275

CCS(=O)(=O)N1CC=C(c2cnc(N)c(C(=O)O)n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.41
ATR Q13535 7/20 0.40
MMP2 P08253 3/20 0.39
MMP3 P08254 3/20 0.39
PRKDC P78527 2/20 0.39
JAK1 P23458 1/20 0.38
CCNE2 O96020 2/20 0.38
CCNE1 P24864 2/20 0.38
CDK2 P24941 2/20 0.38
GSK3B P49841 2/20 0.38
EGLN1 Q9GZT9 5/20 0.37
ATM Q13315 2/20 0.37
CHEK1 O14757 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617489 0.89 GSK3B (0.44) PRMT5ATRMMP2MMP3PRKDC
SCHEMBL617161 0.81 ATR (0.44) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL615057 0.81 ATR (0.58) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL615838 0.80 ATR (0.60) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL614657 0.80 ATR (0.44) ATRPRKDCJAK1CCNE2CCNE1
SCHEMBL617640 0.79 ATR (0.60) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL618705 0.77 ATR (0.44) PRMT5ATRPRKDCCCNE2CCNE1
SCHEMBL616594 0.77 ATR (0.62) ATRPRKDCCCNE2CCNE1CDK2
SCHEMBL617695 0.77 ATR (0.62) PRMT5ATRPRKDCJAK1CCNE2
SCHEMBL615211 0.74 ATR (0.57) PRMT5ATRMMP2MMP3PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 PRMT5 529/4885ATR 1/4885MMP2 4585/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 PRMT5 529/4885ATR 1/4885MMP2 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.